Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 16/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 3/20 | 0.43 |
| ▸ | FNTB | P49356 | 3/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183718 | 0.75 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7512747 | 0.75 | CYP11B1 (0.63) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL3578563 | 0.75 | FNTA (0.36) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL3568027 | 0.73 | HTT (0.51) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL7650703 | 0.72 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL8388781 | 0.72 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL8388778 | 0.72 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL3822425 | 0.70 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8812550 | 0.70 | CYP19A1 (0.39) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8189671 | 0.69 | FNTA (0.60) | CYP11B1CYP11B2CYP19A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110764-A1 | Inhibitors of prenyl-protein transferase | STUMP CRAIG A (US) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110764-A1 | Inhibitors of prenyl-protein transferase | FNTA, KRAS, PTAR1 | CYP11B1 2149/4885CYP11B2 2804/4885CYP19A1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.